Pharma: Other News To Note

 Almirall SA, of Barcelona, Spain, said the European Commission granted marketing approval to Eklira/Bretaris Genuair (aclidinium 322 mcg twice daily) in European Union member states, plus Iceland and Norway, for chronic obstructive pulmonary disease. It will be used as a maintenance bronchodilator treatment to relieve symptoms of the disease.